― Friday, 12th June 2020 Availing Patent Benefits – A ‘Status’ Check!
Every patent office provides certain benefits to Patent Applicants if they meet certain criteria (with respect to entity size, gross income and others). These benefits may be patent fee discounts or speedy examination processes.
This article touches upon the benefits extended by IPO, USPTO and EPO to entities based on their status.
― Wednesday, 27th May 2020 Not an Equal world for AI - No Inventorship for them!
With Artificial intelligence (AI) replacing humans in myriad sectors and operational aspects, it is not surprising that AI is able to concoct its own inventions. AI-generated inventions are (and may become) the norm, however, awarding inventorship to AI under the current patent system is far-fetched. So, is it justifiable denying patent rights to the actual inventor for inventions created by AI or does the patent system merely operate on the fact that AI is a machinewith no capability to exercise legal rights even if given any, and therefore unfit to hold inventorship for its creations.
― Wednesday, 27th May 2020 First Filing in India: A Requirement or a Choice?
Indian resident inventors may decide to file patent applications in multiple countries including India or entirely disregard India and go international! This may be due to weak market strength/poor demand for the product/invention in the country.
As per Indian Patents Act, it is mandatory to obtain an Foreign Filing License (FFL) if an Indian resident inventor decides to first file in a foreign country bypassing Indian Patent Office(IPO) . As per the rules, within 21 days of requesting for an FFL, the IPO, usually, either issues the FFL certificate or rejects the FFL request.
Another option is to first file in India and then wait for a cooling-off period (six weeks!) before attempting to file in a foreign country. In this case, an FFL is not required.
― Friday, 22nd May 2020 The Missing Link - IT Act and IPR Laws
Cyber laws are defined under the Information Technology (IT) Act of 2000 encompassing legal and regulatory aspects of the internet and the world wide web. However, certain entities/intermediaries such as e-commerce websites, search engines, and data aggregators sometimes come under scrutiny for violation of IPR laws when seen under the light of IT Act. Hence, protection to intermediaries from liability, arising out of content posted by users, needs be addressed by creating nexus between IT Act and IPR laws.
― Wednesday, 20th May 2020 Keeping an Eye on India - USA’s IP Priority Watch List
India has been grappling with big IP giants such as the US to establish its stance on the IP front. Owing to a fallible IP regime, India has yet again come under the US’s Priority Watch List and is required to meet certain expectations of the US in terms of trade and other IPR related policies. However, the question still remains whether India, being a sovereign nation, should let itself be subdued by the US or have its own say in IP matters concerning the nation.
― Tuesday, 28th June 2022 Novo Sues Orbicular to Block Copies of Saxenda Weight-Loss Drug
Novo Nordisk AS alleges that a generic version of Saxenda proposed by Orbicular Pharmaceutical Technologies Pvt. Ltd. infringes 18 patents for the injectable weight-loss treatment, according to a federal lawsuit in Delaware.
― Tuesday, 28th June 2022 Bausch, Insud’s Chemo Sue Encube to Block Copies of Nuvessa Drug
Insud Pharma SL’s Chemo Research SL unit and Bausch Health Cos. allege that a generic version of Nuvessa proposed by Encube Ethicals Private Ltd. infringes seven patents for the bacterial vaginosis treatment.
― Tuesday, 28th June 2022 Lyft Wins Pause In Patent Case Pending Tribunal Review
Lyft Inc. convinced a Texas federal court Friday to pause a lawsuit accusing the rideshare company of infringing four patents for location and communication technology, giving an administrative tribunal time to wrap up re-examining several of the patents first.
― Tuesday, 28th June 2022 CAFC Sends Centripetal Back to Drawing Board in Case with Cisco Due to Judge’s Stock
Centripetal Networks will have to start from square one in its long-running case against Cisco after the U.S. Court of Appeals for the Federal Circuit (CAFC) on Thursday vacated a judge’s decision awarding Centripetal enhanced damages and royalties exceeding $2.75 billion.
― Monday, 27th June 2022 Dr Reddy’s settles therapeutic drug patent litigation with Indivior, Aquestive Therapeutics
The re-launch came on the heels of a favourable decision issued by the United States Court of Appeals for the Federal Circuit concluding that Indivior had not shown that it is likely to succeed on its claim that Dr Reddy’s product infringes US Patent No. 9,931,305. The Federal Circuit’s decision vacates the District Court’s preliminary injunction that had prohibited Dr Reddy’s from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. Buprenorphine and naloxone sublingual film is generally indicated for treatment of opioid dependence.